SCHEMBL784535

SCHEMBL784535

Cc1cc(N2CCC(N(C)C(=O)c3ccc4c(c3)[C@H](N(C)C(=O)c3cccc(F)c3Cl)CC4)CC2)nc(C)n1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TAF1 P21675 3/20 0.41
CECR2 Q9BXF3 3/20 0.41
BRD9 Q9H8M2 3/20 0.41
SPR P35270 2/20 0.37
TLR9 Q9NR96 1/20 0.36
TLR8 Q9NR97 1/20 0.36
TLR7 Q9NYK1 1/20 0.36
USP30 Q70CQ3 1/20 0.34
HCRTR1 O43613 3/20 0.34
HCRTR2 O43614 3/20 0.34
GBA1 P04062 1/20 0.34
AURKA O14965 1/20 0.33
CCR3 P51677 1/20 0.33
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
PDE4B Q07343 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL784412 0.92 TAF1 (0.37) TAF1CECR2BRD9TLR9TLR8
SCHEMBL784117 0.92 TAF1 (0.39) TAF1CECR2BRD9TLR9TLR8
SCHEMBL785700 0.90 TAF1 (0.39) TAF1CECR2BRD9SPRTLR9
SCHEMBL785207 0.89 TAF1 (0.43) TAF1CECR2BRD9SPRTLR9
SCHEMBL785525 0.88 TAF1 (0.42) TAF1CECR2BRD9SPRTLR9
SCHEMBL785799 0.88 TAF1 (0.42) TAF1CECR2BRD9SPRTLR9
SCHEMBL785520 0.88 WDR5 (0.39) TAF1CECR2BRD9SPRTLR9
SCHEMBL785486 0.88 TAF1 (0.44) TAF1CECR2BRD9SPRTLR9
SCHEMBL785180 0.85 F10 (0.38) MEN1KMT2APDE4BL3MBTL1
SCHEMBL784144 0.84 TAF1 (0.40) TAF1CECR2BRD9SPRTLR9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US claimed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US claimed
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071461-A1 Substituted Benzamide Compounds BDKRB1, BDKRB2, HRH2 TAF1 2144/4885CECR2 888/4885BRD9 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.